Systemic Therapy for Metastatic Renal-Cell Carcinoma.
Choueiri TK, Motzer RJ.
N Engl J Med. 2017 Jan 26;376(4):354-366. doi: 10.1056/NEJMra1601333.
Nephrogenic epistaxis.
Kumar R, Sikka K, Kumar R, Chatterjee P.
Singapore Med J. 2014 Jul;55(7):e112-3. doi: 10.11622/smedj.2013185.
[Gemcitabine-induced thrombotic microangiopathy].
Teixeira L, Debourdeau P, Zammit C, Estival JL, Pavic M, Colle B.
Presse Med. 2002 Apr 27;31(16):740-2.
TAF1D promotes tumorigenesis and metastasis by activating PI3K/AKT/mTOR signaling in clear cell renal cell carcinoma.
Hu X, Chen L, Liu T, Wan Z, Yu H, Tang F, Shi J, Chen Z, Wang X, Yang Z.
Cell Signal. 2024 Dec;124:111425. doi: 10.1016/j.cellsig.2024.111425. Epub 2024 Sep 20.
Tumor-to-tumor metastasis of the central nervous system.
Erdogan H, Aydin MV, Tasdemiroglu E.
Turk Neurosurg. 2014;24(2):151-62. doi: 10.5137/1019-5149.JTN.8317-13.1.
Follow-up Management of Cystectomy Patients.
Reddy M, Kader K.
Urol Clin North Am. 2018 May;45(2):241-247. doi: 10.1016/j.ucl.2018.01.001.
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
Murphy KA, James BR, Guan Y, Torry DS, Wilber A, Griffith TS.
Hum Vaccin Immunother. 2015;11(7):1612-20. doi: 10.1080/21645515.2015.1035849.
Cadherins in renal cell carcinoma.
Heicappell R.
Anticancer Res. 1999 Mar-Apr;19(2C):1501-4.
Immunotherapy for Resected Pulmonary Metastases.
Morse MA.
Thorac Surg Clin. 2016 Feb;26(1):69-78. doi: 10.1016/j.thorsurg.2015.09.009.
[Metastatic renal failure].
Cluzel P, Enache I, Roche-Lachaise I, Justrabo E.
Nephrol Ther. 2006 Feb;2(1):41-6. doi: 10.1016/j.nephro.2005.08.006. Epub 2005 Nov 8.
